Last reviewed · How we verify
low dose peroral misoprostol
Misoprostol is a prostaglandin E1 analogue that stimulates gastric mucus secretion and reduces gastric acid production to protect the gastrointestinal mucosa.
Misoprostol is a prostaglandin E1 analogue that stimulates gastric mucus secretion and reduces gastric acid production to protect the gastrointestinal mucosa. Used for Prevention of NSAID-induced gastric ulcers, Gastroprotection in patients requiring chronic NSAID therapy.
At a glance
| Generic name | low dose peroral misoprostol |
|---|---|
| Sponsor | University Medical Centre Ljubljana |
| Drug class | Prostaglandin E1 analogue |
| Target | Prostaglandin E receptor (EP receptor) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Misoprostol binds to prostaglandin receptors on gastric epithelial cells, enhancing mucus and bicarbonate secretion while simultaneously decreasing gastric acid secretion. At low oral doses, it is used primarily for gastroprotection, particularly in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) who are at risk for peptic ulcer disease. The drug also has uterotonic properties at higher doses, but low-dose formulations are marketed for GI protection.
Approved indications
- Prevention of NSAID-induced gastric ulcers
- Gastroprotection in patients requiring chronic NSAID therapy
Common side effects
- Diarrhea
- Abdominal pain/cramping
- Nausea
- Flatulence
Key clinical trials
- Comparison of the Effectiveness, Safety, and Satisfaction of Different Methods for Labor Induction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose peroral misoprostol CI brief — competitive landscape report
- low dose peroral misoprostol updates RSS · CI watch RSS
- University Medical Centre Ljubljana portfolio CI